A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis.


Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
14 10 2020
Historique:
received: 06 07 2020
accepted: 18 09 2020
revised: 16 09 2020
pubmed: 16 10 2020
medline: 7 5 2021
entrez: 15 10 2020
Statut: epublish

Résumé

Among 382 patients with WHO-defined prefibrotic myelofibrosis (pre-PMF) followed for a median of 6.9 years, fibrotic or leukemic transformation or death accounts for 15, 7, and 27% of cases, respectively. A multistate model was applied to analyze survival data taking into account intermediate states that are part of the clinical course of pre-PMF, including overt PMF and acute myeloid leukemia (AML). Within this multistate framework, multivariable models disclosed older age (>65 years) and leukocytosis (>15 × 10

Identifiants

pubmed: 33056979
doi: 10.1038/s41408-020-00368-1
pii: 10.1038/s41408-020-00368-1
pmc: PMC7566465
doi:

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : MYNERVA project, #21267
Pays : International

Références

Blood. 2017 Jun 15;129(24):3142-3144
pubmed: 28620103
Int J Hematol. 2018 Oct;108(4):411-415
pubmed: 29987745
Oncotarget. 2017 Oct 6;8(60):101735-101744
pubmed: 29254200
Am J Hematol. 2017 Sep;92(9):885-891
pubmed: 28543356
J Clin Oncol. 2011 Aug 10;29(23):3179-84
pubmed: 21747083
Blood. 2017 Jun 15;129(24):3227-3236
pubmed: 28351937
Blood. 2011 May 26;117(21):5710-8
pubmed: 21447832
Stat Med. 2017 Dec 20;36(29):4719-4742
pubmed: 28872690
Haematologica. 2005 Aug;90(8):1128-32
pubmed: 16079113
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood Cancer J. 2018 Nov 7;8(11):104
pubmed: 30405096
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921
Leukemia. 2013 Sep;27(9):1861-9
pubmed: 23619563
PLoS One. 2012;7(4):e35631
pubmed: 22536419
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394

Auteurs

Alessandra Carobbio (A)

FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Paola Guglielmelli (P)

Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Elisa Rumi (E)

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Chiara Cavalloni (C)

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Valerio De Stefano (V)

Institute of Hematology, Catholic University, Rome, Italy.
Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy.

Silvia Betti (S)

Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy.

Alessandro Rambaldi (A)

Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Department of Oncology and Hematology, University of Milan, Milan, Italy.

Maria Chiara Finazzi (MC)

Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

Juergen Thiele (J)

Institute of Pathology, University of Cologne, Cologne, Germany.

Alessandro M Vannucchi (AM)

Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

Ayalew Tefferi (A)

Hematology Division, Mayo Clinic, Rochester, MN, USA.

Tiziano Barbui (T)

FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. tbarbui@fondazionefrom.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH